FEROZ Stock Overview
Engages in the importing, manufacturing, and sale of pharmaceutical products and medical devices in Pakistan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Ferozsons Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | PK₨240.13 |
| 52 Week High | PK₨270.00 |
| 52 Week Low | PK₨133.11 |
| Beta | 0.76 |
| 11 Month Change | -0.21% |
| 3 Month Change | 7.90% |
| 1 Year Change | 46.37% |
| 33 Year Change | -29.07% |
| 5 Year Change | 239.81% |
| Change since IPO | 11,260.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| FEROZ | PK Pharmaceuticals | PK Market | |
|---|---|---|---|
| 7D | -3.6% | -5.2% | -3.4% |
| 1Y | 46.4% | 64.9% | 43.9% |
Return vs Industry: FEROZ underperformed the PK Pharmaceuticals industry which returned 64.9% over the past year.
Return vs Market: FEROZ exceeded the PK Market which returned 43.9% over the past year.
Price Volatility
| FEROZ volatility | |
|---|---|
| FEROZ Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in PK Market | 8.6% |
| 10% least volatile stocks in PK Market | 3.3% |
Stable Share Price: FEROZ has not had significant price volatility in the past 3 months.
Volatility Over Time: FEROZ's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 1,680 | Osman Waheed | ferozsons-labs.com |
Ferozsons Laboratories Limited, together with its subsidiaries, engages in the importing, manufacturing, and sale of pharmaceutical products and medical devices in Pakistan and internationally. The company offers products in various therapeutic areas of anti-fungal, diabetes, anti-viral, cardiometabolic, cough, dermatology, orthopaedic, urology and nephrology, gastrointestinal and liver, antibiotics, and oncology areas. It also provides medical devices in the areas of cardiology, G.I. endoscopy, oncology, peripheral vascular disease, urology, and women's health applications.
Ferozsons Laboratories Limited Fundamentals Summary
| FEROZ fundamental statistics | |
|---|---|
| Market cap | PK₨10.44b |
| Earnings (TTM) | PK₨493.87m |
| Revenue (TTM) | PK₨15.14b |
21.1x
P/E Ratio0.7x
P/S RatioIs FEROZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FEROZ income statement (TTM) | |
|---|---|
| Revenue | PK₨15.14b |
| Cost of Revenue | PK₨9.42b |
| Gross Profit | PK₨5.72b |
| Other Expenses | PK₨5.22b |
| Earnings | PK₨493.87m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 11.36 |
| Gross Margin | 37.77% |
| Net Profit Margin | 3.26% |
| Debt/Equity Ratio | 51.6% |
How did FEROZ perform over the long term?
See historical performance and comparison